Monte Rosa Therapeutics, Inc.
No enriched coverage for $GLUE in the last 7 days.
UBS initiated coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and $19 price target, citing the potential of its drug MRT-8102 for chronic inflammatory diseases. The firm highlights the drug's differentiated profile and the company's atherosclerotic cardiovascular disease opportunity.
H.C. Wainwright reiterated a Buy rating and $25.00 price target on Monte Rosa Therapeutics (GLUE) after positive clinical trial results for MRT-8102. The stock is currently trading at $10.50, down 10% over the past week. Jefferies also raised its price target to $40, maintaining a Buy rating. The company is conducting a phase 2 study for metastatic prostate cancer and expects further clinical data catalysts in 2026 and 2027.
Analysts maintained Buy ratings on Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM). GLUE has a $28.17 avg. price target (147.1% upside), while CGEM has a $35.70 target (141.9% upside). Both have Strong Buy consensus.
Recent GLUE coverage spans financial news, corporate actions and technology.
In the last 30 days, GLUE insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($137). The most active reporter was Bowen Matthew, Principal Accounting Officer, with 1 filing.
Analyst upgrade and higher price target likely lift the stock.
Positive trial data may lift the stock as it exceeds efficacy benchmarks.
Analyst coverage may lift sentiment and support upside potential.
Positive Phase 1 data is likely to lift the stock as investors price in reduced development risk.
The grant may cause slight dilution pressure but is unlikely to move the stock significantly.
AlphAI scores every news story that mentions GLUE with an AI model for sentiment and relevance, and aggregates insider trades from Monte Rosa Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS initiated coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and $19 price target, citing the potential of its drug MRT-8102 for chronic inflammatory diseases. The firm highlights the drug's differentiated profile and the company's atherosclerotic cardiovascular disease opportunity.
1 min readH.C. Wainwright reiterated a Buy rating and $25.00 price target on Monte Rosa Therapeutics (GLUE) after positive clinical trial results for MRT-8102. The stock is currently trading at $10.50, down 10% over the past week. Jefferies also raised its price target to $40, maintaining a Buy rating. The company is conducting a phase 2 study for metastatic prostate cancer and expects further clinical data catalysts in 2026 and 2027.
2 min readAnalysts maintained Buy ratings on Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM). GLUE has a $28.17 avg. price target (147.1% upside), while CGEM has a $35.70 target (141.9% upside). Both have Strong Buy consensus.
1 min readMonte Rosa Therapeutics reported positive Phase 1 results for MRT-8102, showing significant biomarker reductions and no serious adverse events. The data supports its planned Phase 2b study in coronary artery disease. The company forecasts revenue of $88.1M and earnings of $15.2M by 2029, with current losses of $161.1M and revenue of $28.7M.
2 min readMonte Rosa Therapeutics (GLUE) granted inducement equity awards to five new employees, including options for 86,725 shares and restricted stock units for 19,150 shares. The awards vest over time, subject to continued employment. The grants were approved by the compensation committee under Nasdaq Rule 5635(c)(4).
1 min readMonte Rosa Therapeutics (GLUE) announced Phase 2 trials for MRT-8102 after positive Phase 1 results. The GFORCE-1 trial assessed the daily treatment's efficacy. Shares rose in premarket trading.
1 min readMonte Rosa Therapeutics reported positive Phase 1 results for MRT-8102, showing 80-90% NEK7 degradation and reduced inflammation markers. The study had no serious adverse events. Phase 2 trials are planned for 2026-2027.
1 min readMonte Rosa Therapeutics (GLUE) will present Phase 1 study results for MRT-8102, a treatment for elevated cardiovascular disease risk, on October 1. The presentation will include safety and activity data from a 4-week trial. The webcast will be available on the company's website and archived for 30 days.
2 min readMonte Rosa Therapeutics (GLUE) received a $50M milestone payment from Novartis (NVS) for the first patient dosed in a Phase 2 trial of MRT-6160 for Sjögren’s disease. The deal could be worth up to $2.1B. Monte Rosa reported Q2 2026 revenue of $9M, up from $23.2M a year earlier, with a net loss of $43.4M. The company has multiple clinical trials ongoing and $626M in cash.
3 min readMonte Rosa Therapeutics (GLUE) announced that Novartis has initiated a Phase 2 study for MRT-6160 (DDY391) in Sjögren's disease patients. Monte Rosa will receive a $50 million milestone payment. The study is part of a global license agreement where Novartis has exclusive rights to develop and commercialize VAV1 MGDs, with Monte Rosa eligible for up to $2.1 billion in milestones.
2 min read
